Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy

Por Young, Christine S., Clarke, Kathryn M., Kettyle, Laura M., Thompson, Alexander, Mills, Ken I.
Publicado no Oncotarget (2017)

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy

Por Hay, Jodie F., Lappin, Katrina, Liberante, Fabio, Kettyle, Laura M., Matchett, Kyle B., Thompson, Alexander, Mills, Ken I.
Publicado no Oncotarget (2017)

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy

Por Dickson, Glenda J., Liberante, Fabio G., Kettyle, Laura M, O’Hagan, Kathleen A., Finnegan, Damian P. J., Bullinger, Lars, Geerts, Dirk, McMullin, Mary Frances, Lappin, Terry R. J., Mills, Ken I., Thompson, Alexander
Publicado em 2013

Low-dose salinomycin induces anti-leukemic responses in AML and MLL

Por Roulston, Gary D.R., Burt, Charlotte L., Kettyle, Laura M.J., Matchett, Kyle B., Keenan, Heather L., Mulgrew, Nuala M., Ramsey, Joanne M., Dougan, Caoifa, McKiernan, John, Grishagin, Ivan V., Mills, Ken I., Thompson, Alexander
Publicado no Oncotarget (2016)